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ABSTRACT 
 
Human papillomaviruses (HPVs) form a large family of double stranded DNA 
(dsDNA) viruses, some types of which are the major causes of cervical cancer. 
HPV 16 is widely distributed and the most common high-risk HPV type and 
approximately half of the cervical cancers are associated with HPV type 16. Of 
the three HPV 16 encoded oncogenes, the function of E5 in regulating viral 
replication and pathogenesis is less well understood than E6 and E7. The 
microRNAs (miRNAs) are important small noncoding RNA molecules that 
regulate wide range of cellular functions. Some dsDNA viruses, such as SV40 
and human polyomaviruses, have functional viral miRNAs. The functional and 
molecular similarities among dsDNA viruses suggest that HPV could encode 
viral miRNAs, which have not been validated thus far. The aim of this thesis 
was to study the functions of the host miRNAs in HPV 16 oncogene induction 
and identify novel HPV encoded viral miRNAs. We utilized microarray 
technology to investigate the effect of E5 on host miRNAs and mRNAs 
expression in 0–96 hours after E5 induction in a cell line model. Among the 
differentially expressed cellular miRNAs, we further validated the expression of 
hsa-mir-146a, hsa-mir-203, and hsa-mir-324-5p and some of their target 
genes in a time series of 96 hours of E5 induction. Our results indicate that 
HPV E5 expression has an impact through complex regulatory patterns of 
gene expression in the host cells, and part of those genes is regulated by the 
E5 protein. Second, high throughput sequencing was used to identify 
virus-encoded miRNAs. We prepared small RNA sequencing libraries from ten 
HPV-associated cervical lesions, including cancer and two HPV-harboring cell 
lines. For more flexible analysis of the sequencing data we developed 
miRSeqNovel, an R based workflow for miRNA sequencing data analysis, and 
applied it to the sequencing data to predict putative viral miRNAs and 
discovered nine putative papillomavirus encoded miRNAs. Viral miRNA 
validation was performed for five candidates, four of which were successfully 
validated by qPCR from cervical tissue samples and cell lines: two were 
encoded by HPV 16, one by HPV 38, and one by HPV 68. The expression of 
two HPV 16 miRNAs was further supported by in situ hybridization, and 
colocalization with p16INK4A staining, a marker of cervical neoplasia. 
Prediction of cellular target genes of HPV 16 encoded miRNAs suggests that 
they may play a role in cell cycle, immune functions, cell adhesion and 
migration, development and cancer, which were also among the functions 
targeted by the E5 regulated host cell mRNA and miRNAs. Two putative viral 
target sites for the two validated HPV 16 miRNAs were mapped to the E5 gene, 
one in the E1 gene, two in the L1 gene, and one in the long control region 
(LCR).  
 
 
  
	  
	  
 
ABBREVIATIONS 
 
 
5'    five prime 
3'    three prime 
cDNA   complementary DNA 
CGH   comparative genomic hybridization 
ChIP-on-chip on-chip chromatin immunoprecipitation 
ChIP-Seq chromatin immunoprecipitation followed by next generation 
sequencing 
CIN   cervical intraepithelial neoplasia  
CLIP-Seq  crosslinking immunoprecipitation-high-throughput sequencing  
Cy3   cyanine 3 
Cy5   cyanine 5 
DAVID  Database for Annotation, Visualization and Integrated 
Discovery 
DNA   deoxyribonucleic acid 
dsDNA   double stranded DNA 
FDR   false discovery rate 
FFPE   formalin-fixed paraffin-embedded 
GEO   Gene Expression Omnibus 
GO    Gene Ontology 
HaCaT   immortal human keratinocyte cell 
HeLa   immortal human cervical cancer cell 
HPK II    HPV 16 immortalized human keratinocyte cell 
HPK IA   HPV 16 immortalized human keratinocyte cell  
HPV    human papillomavirus  
iCLIP   individual nucleotide resolution CLIP 
KEGG   Kyoto Encyclopedia of Genes and Genomes 
LCR   long control region  
logFC   log2 fold change  
MCF7   immortal human breast cancer cell 
miRNA   microRNA 
miRNA*  star microRNA 
miRNP   microRNA ribonucleoprotein complex 
mRNA   messenger RNA 
NCBI    National center for biotechnology information 
	  
	  
NGS   next generation sequencing 
nt    nucleotide  
ORF   open reading frame 
p53   tumor protein 53 
PAR-CLIP photoreactive nucleotide-enhanced crosslinking and 
immunoprecipitation 
pRb   retinoblastoma protein 
pri-miRNAs  primary miRNAs 
pre-miRNAs precursor miRNAs 
pol II    RNA polymerase II  
RNA   ribonucleic acid 
RBP   RNA-binding protein 
RNA-Seq  Transcriptome sequencing  
SCC   squamous cell carcinoma  
SMRT   single molecule real time 
SNP   single nucleotide polymorphism  
SNV    single nucleotide variant 
SOLiD   Sequencing by Oligonucleotide Ligation and Detection 
SV40   simian virus 40  
U2OS   immortal human osteosarcoma cell 
UTR   untranslated region 
 
 
9	  
	  
 
1. Introduction 
1.1 Human Papillomavirus (HPV) 
Human papillomaviruses (HPVs) belong to the family of Papillomaviridae and 
they preferentially infect keratinocytes of mucous membranes or skin and 
cause numerous benign and malignant lesions at different anatomical 
locations (Doorbar et al. 2012). Close to 200 HPV types have been 
characterized, which are classified into low-risk and high-risk types (Bernard et 
al. 2010). Low-risk HPV types, such as HPV 6 and 11, can cause benign warts 
or condylomata acuminata (Lorincz et al. 1992). High-risk HPV types, such as 
16 and 18, can cause squamous epithelial lesions that have potential to 
become malignant (zur Hausen 2009). HPV infection is considered the most 
common sexually transmitted disease worldwide. It is not rare to have 
co-infection with multiple HPV types or sequential infection with 
phylogenetically related types (Chaturvedi et al. 2011). Two commercial 
prophylactic vaccines have shown success in preventing HPV infections. 
However, it is noteworthy that they do not work against all cancer-related types, 
and do not cure acquired infections. There are some challenging aspects 
limiting HPV research: first, it is difficult to isolate viral particles from tissue 
samples and, second, HPVs cannot replicate in conventional cell culture 
systems (Chow et al. 2010). 
1.1.1 HPV genome 
HPVs are a group of small non-enveloped DNA tumor viruses with a double 
stranded circular DNA genome approximately 8,000 base pairs in size (Zheng 
et al. 2006). HPV genome can be divided, in general, into three major regions: 
an early region with ORFs, a late region and a long control region (LCR). The 
early region encodes six nonstructural regulatory proteins (E1, E2, E4, E5, E6, 
and E7). The late region locates downstream of the early region and encodes 
L1 (major) and L2 (minor) structural capsid proteins. The LCR region has no 
protein-coding function, but provides the promoter and multiple transcription 
factor binding sites involved in the regulation of viral transcription and 
replication (Zheng et al. 2006).  
E1 and E2 are involved in viral DNA replication and the regulation of early 
transcription (Doorbar et al. 2012). E4 is considered to function in virion 
release (Doorbar et al. 1997). E5, E6, and E7 are oncogenes and their 
expression induce cell immortalization and transformation (Doorbar 2006). A 
characteristic in cervical carcinogenesis by high-risk HPVs is that viral 
genomes are commonly integrated into the host cell genome, resulting in the 
loss of functional viral E2 gene (Romanczuk et al. 1992).  
1.1.2 HPV oncogenes 
The most prevalent HPV type found in cervical cancer is HPV 16, which 
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encodes three oncogenes: E5, E6, and E7, which are associated with the 
proliferation of suprabasal epithelial cells (Moody et al. 2010). The E6 and E7 
can bind to and stimulate the degradation of the tumor suppressors p53 
(Werness et al. 1990) and pRb (Dyson et al. 1989). Their oncogenic potentials 
are largely correlated with these interactions (Heck et al. 1992; Nguyen et al. 
2002), but their interference with the functions of other intracellular proteins 
plays an important role as well (Balsitis et al. 2006; Shai et al. 2007). The 
expression of cyclin-dependent kinase inhibitor p16INK4A (also known as p16 
or CDKN2A) is upregulated due to the interaction of E7 and pRb, and can be 
used as a marker of persistent high-risk HPV infection (Klaes et al. 2001). The 
expression of E6 and E7 proteins can be repressed by a high expression level 
of E2 protein, so the loss of E2 gene upon integration of the viral genome into 
the host genome will lead to increased expression of E6 and E7 (Romanczuk 
et al. 1992). 
 
Figure 1. Schematic representation of HPV 16 oncogene activities 
HPV 16 E6 and E7 bind and degrade p53 (Werness et al. 1990) and pRb 
(Dyson et al. 1989). E7 and pRb interaction also leads to higher expression of 
p16. E2 can prevent high expression of E6 and E7 (Romanczuk et al. 1992). 
E2 has binding sites in LCR region to regulate E6 and E7 expression. 
 
The role of the E5 oncoprotein in the transformation process is less well 
studied and understood. The HPV 16 E5 coding sequence is frequently, but 
not always, deleted when the viral genome is integrated into the host cell 
genome (Schmitz et al. 2012). E5 has been reported to transform 
tissue-cultured murine fibroblasts and keratinocytes alone (Pim et al. 1992; 
Straight et al. 1993) as well as to enhance the immortalization potential of E6 
and E7 proteins (Stöppler et al. 1996). HPV 16 E5 contributes to tumorigenicity 
in nude mice (Leechanachai et al. 1992) and contributes to skin 
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carcinogenesis in E5 transgenic mice (Genther Williams et al. 2005; Maufort et 
al. 2007). It has been suggested that HPV 16 E5 acts as an oncogene 
primarily by enhancing the activation of the epidermal growth factor receptor in 
a ligand-dependent manner (Straight et al. 1993; Crusius et al. 1997; Crusius 
et al. 1998; Tomakidi et al. 2000), but the mechanisms of E5 action have not 
yet been established, due to a limited number of studies. Very recently it was 
suggested that E5 alone might have a high oncogenic potential, because E5 
transgenic mice were shown to develop cervical cancer after prolonged 
estrogen treatment (Maufort et al. 2010). Additionally, HPV 16 E5 potentiated 
the effect of E6 and E7 oncogenes in inducing cervical disease (Stöppler et al. 
1996). 
Our group has previously shown that E5 alters the expression of a number of 
host protein-coding genes in cultured human keratinocytes (Kivi et al. 2008). 
Specifically, we observed that genes implicated in cell motility and cell 
adhesion are affected by E5 expression. We also showed enhanced motility of 
E5 expressing cells in an in vivo wound healing experiment, which suggests 
that E5 is implicated in the carcinogenic process (Kivi et al. 2008).  
Establishment of HPV infection requires the host cell to pass early cell cycle 
progression and enter M phase (mitosis) in the undifferentiated proliferating 
basal cell layer (Pyeon et al. 2009). Progeny virus production occurs 
exclusively in differentiated suprabasal layers of the epithelium, and cannot 
take place if epithelial differentiation is disturbed. Regulation of papillomavirus 
replication and successful progeny virus production, or pathogenesis of 
HPV-associated diseases is not completely understood. The environment of 
epithelial cells committed to differentiate is crucial and essentially involves 
regulatory changes in mRNA and microRNA expression (Calin et al. 2006).  
1.1.3 Biology of cervical cancer  
Cervical cancer is the third most common cancer in women worldwide (Jemal 
et al. 2011). Cervical HPV infection is a common sexually transmitted infection. 
It is an evolving process from conversion of normal cervical epithelium to 
cervical intraepithelial neoplasia (CIN) that is subsequently transformed to 
invasive cervical cancer (Bodily et al. 2011). Squamous cell carcinoma (SCC) 
of the cervix develops through CIN grades 1-3, which are pre-malignant 
phases that are well defined by cytological examination: CIN1 (mild dysplasia) 
to CIN2 (moderate dysplasia) to CIN3 (severe dysplasia/carcinoma in situ) 
(Moody et al. 2010). Although most women will at some time be infected with 
HPV, very few will progress to invasive disease. A proportion of all CIN grades 
may regress, but CIN3 is considered a pre-cancer with potential to progress to 
cervical cancer (Schiffman et al. 2007). Further, cervical cancer is associated 
with HPV. Persistent infection by the high-risk HPV types is a prerequisite for 
cervical cancers, but not sufficient cause of cervical cancer (Woodman et al. 
2007). The concurrent or sequential detection of different HPV types is 
common. Two HPV vaccines are currently on the market, both of which protect 
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against the HPV 16 and 18. Although most HPV infections do not progress to 
cancers, the high prevalence still makes HPV-related cancers among the most 
common malignancies.	  
1.1.4 HPVs and cervical cancer 
High-risk HPV infection plays a critical role in the pathogenesis of cervical 
cancer in women worldwide and is an important etiologic agent in other 
anogenital cancers (zur Hausen 2002; Woodman et al. 2007). High-risk HPV 
genotypes, including HPV 16, 18, 31 and others, cause almost all cervical 
cancers and their immediate precursors worldwide (Schiffman et al. 2007). 
High-risk human papillomavirus types 16 and 18 are known to be associated 
with more than 70% of cervical cancers (zur Hausen 2009; Guan et al. 2012).  
Although HPVs remain in episomal form in benign, precancerous lesions, they 
frequently integrate into the cellular genome in cervical cancers, and this 
integration may play a role in cancer development (Pett et al. 2007). Variable 
portions of the viral genome are present in the integrated genomes, but 
common features include sustained expression of E6/E7 under the control of 
their viral promoter as well as loss of the E2 gene (zur Hausen 2000). As 
described above, HPV E2 is also a transcription repressor that can directly 
bind to and repress the E6/E7 promoter of high-risk HPVs (Romanczuk et al. 
1990). The loss of E2 expression causes the oncogene E6 and E7 expression 
to reduce p53 and pRb expression, which in turn stimulates cellular 
proliferation. As such, disruption of the E2 gene has been mechanistically 
linked to malignant progression of HPV-associated cancers. High-risk HPV E6 
and E7 proteins are universally expressed in human HPV-positive cancers in 
vivo and function cooperatively in vitro, thus establishing these proteins as the 
primary viral oncogenes (zur Hausen 2002). The viral E5 protein can further 
contribute to HPV malignancy (DiMaio et al. 2001), and carries an independent 
carcinogenic potential in transgenic mouse models (Maufort et al. 2007; 
Maufort et al. 2010). Deregulated expression of the high-risk HPV oncogenes 
is a critical event in the progression of HPV-positive lesions (Gao et al. 2010). 
1.2 microRNA biogenesis and functions 
MiRNAs (miRNAs) are short (18-25 nucleotides) noncoding RNAs that 
post-transcriptionally regulate messenger RNA (mRNA) expression. Lee et al. 
discovered the first miRNA, lin-4 in C. elegans, in 1993 (Lee et al. 1993), and 
to date, over 21 thousands miRNAs, including 1,600 human miRNAs, have 
been identified (miRBase release 19, 2012 (Kozomara et al. 2011)). They play 
important roles in cellular processes such as immune response, cell 
differentiation and proliferation, metabolism, apoptosis, and oncogenesis (Krol 
et al. 2010). MiRNAs are important players in oncogenesis (Esquela-Kerscher 
et al. 2006). Aberrantly expressed miRNAs can act as oncogenes or tumor 
suppressor genes. 
Although our ability of predicting miRNA targets is still imperfect, it is known 
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that in animals, the 5’ end of an miRNA plays the crucial role in selecting the 
targets (Lewis et al. 2003). The 2nd-8th nucleotides (minimally 2nd-7th) from the 
5’ end of the miRNA is the so-called “seed” region. The seed region binds to 
the 3’ UTR region of the target mRNAs, leading to degradation of the target 
mRNA or blocking its translation (Valencia-Sanchez et al. 2006). Though most 
miRNA target sites in animals are found in 3’ UTR, miRNAs can also bind 
either in 5’ UTR or coding region (Kumar et al. 2012). Many computational 
algorithms for prediction of miRNA targets are based on this rule (Sethupathy 
et al. 2006). Furthermore, if the potential binding sites in the 3’ UTRs are 
evolutionally conserved cross species, the target mRNAs are considered as 
conserved targets. Because of short sequences in the seed region, the 
prediction suggests that one miRNA can regulate even hundreds of target 
mRNAs and many genes are putative targets of more than one miRNA, which 
has also been confirmed by experimental validations (Hsu et al. 2011). 
MicroRNA expression is altered in a number of human diseases spanning from 
psychiatric disorders (Maes et al. 2009) to several cancers (He et al. 2005). 
Moreover, they play a major role in regulating host gene expression in various 
viral infections (Roberts et al. 2010).  
1.2.1 Human microRNA biogenesis 
MiRNAs are found in the human genome as independent loci or within intronic 
regions of other genes (Cai et al. 2004; Kim et al. 2007) usually transcribed by 
RNA polymerase II (pol II) as primary miRNAs (pri-miRNA) (Lee et al. 2004). 
Pri-miRNAs are several kilobases long and may contain one to several hairpin 
structures for multiple individual mature miRNAs. Pri-miRNAs are cleaved by 
RNase III-type enzyme in the nucleus, named Drosha, to at least one or 
several precursor miRNAs (pre-miRNAs). These pre-miRNAs are exported 
from the nucleus in a process involving the Exportin-5 protein (Kim et al. 2009). 
Intronic pre-miRNAs are generated as a product of splicing of the host gene 
(Berezikov et al. 2007). Each pre-miRNA forms a hairpin structure, which 
encodes two products, one mature, and one star miRNA (miRNA*). In the 
cytoplasm, the pre-miRNA hairpins are cleaved by the RNase III enzyme Dicer 
(Murchison et al. 2004), and the mature miRNAs are incorporated into the 
RNA-induced silencing complex (RISC), where they bind to their targets 
(Schwarz et al. 2003). Typically, miRNA* is less likely to associate with RISC 
and is usually thought to be degraded based on the lower expression levels 
(Kozomara et al. 2011). Mature miRNAs almost always have variants, named 
isomiRs, which can also be functional miRNAs (Cloonan et al. 2011). The star 
miRNAs were thought to be non-functional. However, more and more 
evidence shows that miRNA* can be functional and miRNA* may be highly 
expressed (Yang et al. 2011). As a result, the miRNAs nomenclature is 
changing from miR/miR* to -5p/-3p, which identifies the miRNA by its location 
in the 5’/3’ arm of the hairpin. 
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1.2.2 Human microRNA functions 
The main molecular function of miRNA is guiding the RISC complex binding 
target mRNAs, inhibiting translation, and/or cleavage of target mRNA (Volinia 
et al. 2010). Each miRNA can potentially target several mRNAs. Studies have 
shown that a single miRNA can directly down-regulate the production of even 
hundreds of proteins either by repression of translation and mRNA 
degradation (Hsu et al. 2011). The seed sequence in the 3'UTR of target 
mRNA has been confirmed to act as the main motif of miRNA-mediated 
regulation of protein production (Volinia et al. 2010).  
Deregulation of miRNA expression emerges as the main mechanism that 
triggers the loss or gain of function in cancer cells (Calin et al. 2006). With this 
knowledge, it now seems obvious that aberrant expression of miRNAs is 
involved in cancer as well as other human diseases (Esquela-Kerscher et al. 
2006). Multiple miRNAs are deregulated in human disease, supporting the 
hypothesis that miRNAs are involved in the initiation and progression of 
disease (Jiang et al. 2009). Recent data have shown that miRNA deregulation 
or mutations correlate with various human diseases, and that miRNAs can 
function as tumor suppressors and oncogenes (Visone et al. 2009).  
1.2.3 miRNAs in carcinogenesis and in human cancers 
Studies have shown that the overexpression of miRNAs can down-regulate a 
tumor suppressor or other genes involved in cell growth or differentiation, 
thereby contributing to tumor formation by stimulating proliferation, 
angiogenesis, and/or invasion (Zhang et al. 2007). miRNAs can act as 
oncogenes, so-called “oncomirs” (Visone et al. 2007; Veronese et al. 2010). 
Similarly, the function of miRNAs in diseases is dependent on their targets for 
mRNA, where they might act as oncogenes or tumor suppressors. It is 
interesting to note that some miRNAs may have dual functions as both tumor 
suppressors and oncogenes (Gebeshuber et al. 2009), depending on the 
context. Specific upregulated or downregulated miRNAs have been shown to 
correlate with particular tumor types (Volinia et al. 2006). Altered miRNA 
expression profiles have been reported in breast cancer (Iorio et al. 2005), 
cervical cancer (Xie et al. 2012), colon cancer (Borralho et al. 2011), lung 
cancer (Hayashita et al. 2005), ovarian cancer (Iorio et al. 2007), prostate 
cancer (Nadiminty et al. 2012), and thyroid papillary carcinomas (Pallante et al. 
2006). Moreover, some studies have suggested that miRNAs have the 
potential as biomarkers for diagnosis, prognosis, and cancer therapeutics in a 
variety of human diseases (Visone et al. 2011).  
However, the detailed molecular basis of miRNA-mediated gene regulation is 
not fully understood and their role in tumor genesis remains largely unknown. 
The consistent deregulation of several miRNAs in disease will also affect 
expression of their gene targets. The identification and validation of targets of 
the deregulated miRNAs is essential to understand the molecular and 
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biological functions that are influenced as the function of each miRNA is 
dictated by its own targets (Volinia et al. 2010). Because dysregulation of 
miRNA has been associated with various diseases, the identification of 
specific regulators of miRNAs will be helpful in developing new therapeutic 
agents (Shenouda et al. 2009). 
1.2.4 Cervical cancer and cellular miRNA 
Although high-risk HPVs are associated with cervical cancer, a HPV infection 
alone is not sufficient to induce the malignant transformation of HPV-infected 
cervical epithelial cells (zur Hausen 2002). The expression of many cellular 
genes and miRNAs take place in carcinogenesis. Several host miRNA 
expression profiles in cervical cancer have been explored to identify specific 
miRNAs that are important for carcinogenesis. Differentially expressed cellular 
miRNAs in cervical cancer tissue or cervical cancer-derived cells have been 
previously reported (Lui et al. 2007; Wang et al. 2008; Ma et al. 2012; Gocze et 
al. 2013; Wilting et al. 2013). Several upregulated miRNAs have been 
recognized; including hsa-mir-21 (Yao et al. 2009), hsa-mir-127 (Lee et al. 
2008), hsa-mir-146a (Wang et al. 2008; Visone et al. 2009), hsa-mir-182 (Tang 
et al. 2013), hsa-mir-199a (Lee et al. 2008) and hsa-mir-224 (Shen et al. 2013), 
and they may function as oncogenes. Downregulated miRNAs such as 
hsa-mir-34a (Wang et al. 2009; Li et al. 2010; Pang et al. 2010; Gocze et al. 
2013), hsa-mir-124 (Wilting et al. 2010), hsa-mir-143 (Lui et al. 2007; Wang et 
al. 2008; Lajer et al. 2012), hsa-mir-145 (Wang et al. 2008; Lajer et al. 2012), 
hsa-mir-200a (Hu et al. 2010), hsa-mir-214 (Yang et al. 2009) and hsa-mir-218 
(Martinez et al. 2008; Zhou et al. 2010; Yamamoto et al. 2013) have been 
identified and their function as tumor suppressors in cervical cancer 
carcinogenesis has been suggested. 
Downregulation of human miR-218 was specifically addressed to the HPV 16 
E6 oncogene in HPV-positive cell lines, cervical lesions, and cancer tissues 
(Martinez et al. 2008; Yu et al. 2012). Human miR-218 targets the expression 
of its target gene LAMB3, which has a role in enhancing cellular migration and 
tumorigenicity (Zhou et al. 2010; Yamamoto et al. 2013). Human miR-21 has 
been identified as a cancer-associated miRNA and is overexpressed in many 
cancers, including cervical cancer (Lui et al. 2007; Wang et al. 2008). It was 
recently shown that inhibition of hsa-mir-21 in HPV 18-containing HeLa 
cervical cancer cells causes a strong suppression of cell proliferation (Yao et al. 
2009). Downregulation of hsa-miR143 in cervical cancer cell lines has been 
reported (Lui et al. 2007). It thus seems obvious that, similar to other cancers, 
miRNAs play an important role in the development of cervical cancer.  
1.2.5 Viral microRNA biogenesis 
A number of DNA viruses and some RNA viruses encode their own miRNAs as 
well. Most of the known viral miRNAs are found in herpesviruses (Grundhoff et 
al. 2011). Polyomaviruses (Sullivan et al. 2005), adenoviruses, (Xu et al. 2007) 
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and ascoviruses (Hussain et al. 2008) are also known to encode their own 
miRNAs. The precursor miRNAs can be generated by Drosha/Dicer cleavage 
of primary miRNAs (pri-miRNAs), mirtron, tRNase Z cleavage of tRNA-like 
pri-miRNA, or alternative folding of transfer RNAs (Reese et al. 2010) or small 
nucleolar RNAs (Skalsky et al. 2010). Viral miRNAs are mostly generated from 
pre-miRNA by Dicer cleavage and incorporated into the RISC, similar to host 
miRNAs (Grundhoff et al. 2011). 
To date, no study has been able to identify and validate viral miRNAs in 
papillomavirus infected cells using either standard sequencing (Cai et al. 2006) 
or next generation sequencing techniques (Lui et al. 2007). However, Gu et al. 
(Gu et al. 2011) recently reported prediction of several miRNA in mucosal and 
cutaneous HPVs; but despite considerable efforts, no validated papillomavirus 
miRNAs have been established so far. The lack of an efficient cell culture 
system to study viral replication in the context of epithelial differentiation and 
maturation has complicated miRNA discovery in HPV. 
1.2.6 Viral microRNA functions 
Viral miRNAs can target both viral and cellular mRNAs for downregulation 
(Murphy et al. 2008). The identification of viral targets of viral miRNAs is often 
easier due to the smaller genome size and in some cases the viral miRNAs are 
expressed from transcripts that overlap with the antisense strand of viral genes 
that they regulate. Potential cellular targets for viral miRNAs could be cellular 
genes involved in antiviral defense systems, cell proliferation and survival, 
immune recognition, and stress responses. The viral miRNAs contribute to 
cellular reprogramming by regulating the switch from latent to lytic viral 
infection, and by modulating the immune responses in the infected host 
(Skalsky et al. 2010). Polyomavirus miRNAs target viral early transcripts to 
negatively regulate T antigen expression, and they also promote immune 
evasion by targeting cellular genes involved in host immune response, which 
subsequently leads to enhanced viral replication (Seo et al. 2008; Seo et al. 
2009; Bauman et al. 2011; Lee et al. 2011). All these functions are very 
important for viruses in the establishment of persistent infections. The simian 
virus 40 (SV40) encoded miR-S1 is transcribed from the DNA strand harboring 
the late genes, and is complementary to early T antigen transcripts (Sullivan et 
al. 2005). The cleavage of T antigen function has been further confirmed; 
however, it is unessential for replication of virus. On the other hand, 
downregulation of T antigen transcripts helps virus replication by lowering 
cytotoxic T cell recognition. Thus viral miRNA probably contributes to the 
proper balance of viral gene products at specific phases of the infection, most 
likely during latency. Many viral miRNAs are likely to help viruses cause 
long-term infection by evading the immune response, which is a requisite for 
cancer development (Pfeffer et al. 2006). Instead of being oncogenic, viral 
miRNAs could help mediate the survival of viruses from a cellular immune 
system and thus contribute to tumor genesis. Functional and molecular 
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similarities among double stranded DNA viruses causing long-term latent 
infections, especially SV40 (Sullivan et al. 2005), human polyomaviruses BKV 
and JCV (Seo et al. 2008), and BPCV (Chen et al. 2011), suggest that HPV 
could also encode viral miRNAs. 
1.3 Gene expression profiling technology 
High-throughput technologies, especially microarray and next generation 
sequencing (NGS), are ideal tools to measure gene expression globally and in 
parallel cross sample to understand the complex functional mechanisms 
(Wang et al. 2009). They have changed the way of genetic research from a 
few interesting genes to large-scale investigations, usually the whole genome 
and even metagenomics. Ever since the microarray technology emerged, it 
has been the favorite platform to achieve this aim (Schena et al. 1995).  
Although microarrays and NGS are widely used and have many advantages 
as compared to many traditional technologies, some issues remain to be 
considered. In the early days of these methods, the quality and reproducibility 
of results are the primary concern. With the improvement in technology and 
development of laboratory protocols, the quality of generated data has 
improved and many meta-analyses have been performed using data from 
different laboratories (Krol et al. 2010).  
There is also demand to improve the way the results are interpreted to bring 
them into meaningful biological context. For instance, the aim of gene ontology 
(GO) project is to describe every gene in a set of comprehensive controlled 
terms (Ashburner et al. 2000). Besides that, many other databases contribute 
to the gene annotation, such as KEGG (Kyoto Encyclopedia of Genes and 
Genomes) pathway (Kanehisa et al. 2012). Annotations of model organism 
genomes are much better than other organisms. However, annotations still 
contain numerous errors and need further corrections. The DAVID (Database 
for Annotation, Visualization and Integrated Discovery) is a widely used 
web-accessible tool to analyze the functional annotations behind lists of large 
number of genes (Huang da et al. 2009). 
1.3.1 Microarray  
From its first application for transcriptome analysis (Schena et al. 1995), 
microarray technology has been adapted in many research areas such as 
genotyping, miRNA profiling, SNPs, splicing variant analysis, copy number 
variation, comparative genomic hybridization, and ChIP-on-chip (Fan et al. 
2006).  
The gene expression microarray can measure the expression of tens of 
thousands of mRNAs in a single assay, depending on the microarray design. 
In Agilent and Illumina arrays, the total RNAs are extracted from the biological 
samples, converted into cDNA, and labeled with fluorescent dyes for 
hybridization. After hybridization with the probes fixed onto the microarray 
surface, the fluorescent signal intensities are detected by a laser scanner. The 
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image file is further analyzed to estimate the probe signal intensities. This 
represents the raw microarray data, which is merged with the annotation file to 
build the expression matrix and used for further analysis. 
There are mainly two types of microarrays available for expression analysis: 
spotted microarrays, which deposit pre-synthesized oligonucleotides, or cDNA 
probes (usually PCR products) on the array surface; oligonucleotide 
microarray, which directly synthesize probes or “ink-jet printing” on the surface. 
The most popular commercial microarray platforms are Affymetrix (multiple 
shorter probes target each gene), and Agilent (longer and more specific 
probes (Hughes et al. 2001)). In Agilent microarray, samples can be labeled 
with up to three different dyes and hybridized to the same area in the 
microarray (Pessa et al. 2010). 
There are many options for the bioinformatics analysis of microarray data. In 
general, the following steps are needed: 1) Preprocessing and quality control. 
The intensities in the scanned pictures need to be converted into numbers for 
following steps. The overall data reliability can be improved by checking the 
quality of the microarray image and flagging out low quality spots. 2) 
Normalization of the data. Normalization is necessary to remove the 
unavoidable experimental variations, such as differences in labeling 
efficiencies. 3) Identification of differentially expressed genes. The data are 
fitted into statistical models to test the differential expression levels. The 
outputs of these analytical steps are usually tables of genes with related 
p-values and log2 fold changes (logFC). FDR methods, such as Benjamini–
Hochberg method (Benjamini et al. 1995), can lower the false positive rate of 
the results. 4) Functional annotation analysis. This is done by applying 
functional annotation analysis tools, such as DAVID, to the differentially 
expressed gene lists. And the result will be a list of functional annotations, 
which explain the cellular functions of differentially expressed genes and give 
clues to their biological interpretation (Qian et al. 2012).  
Compared to NGS technologies, microarrays have some disadvantages in 
finding novel transcripts and novel variation because of limitations in probe 
design (Wang et al. 2009). Moreover, the raw data in microarray analysis are 
inferred from hybridization intensity, unlike NGS where it is directly measured. 
On the other hand, bioinformatics analysis methods for microarrays are more 
mature than for NGS, which is still in its developing stages. Another advantage 
of microarrays over NGS is that for low expressed genes, a very large number 
of reads in NGS is needed to perform reliable statistical analysis (Dillies et al. 
2012). 
1.3.1.1 mRNA and miRNA microarrays 
Gene expression profiling is probably the most widely used microarray 
application (Duggan et al. 1999). It is used to explore the expression of a large 
number of genes, often the transcriptome, in order to identify differentially 
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expressed genes in different conditions, such as different cells or treatments, 
or in diseases, such as cancers. However, it also has limitations to investigate 
other essential biological questions, such as posttranscriptional regulation and 
modification of mRNAs.  
The miRNA expression profiling is similar to mRNA but it is affected by the 
unique features of miRNAs, such as the short length, low abundance and 
unequal melting temperatures of mature miRNA (Thomson et al. 2004). It is 
important to distinguish between mature miRNAs and their pri-miRNA and 
pre-miRNAs. Because of the higher sequence similarity of some miRNAs, 
especially among some miRNA families, it is crucial to distinguish between 
molecules where the sequence differs by a single nucleotide. The miRNA 
microarray can be used for quantification of hundreds or thousands miRNAs in 
cell lines or tissues samples. A miRNA expression profiling study could be a 
useful tool to evaluate a detailed molecular analysis of its expression in the 
process of cancer development.  
1.3.2 Next Generation Sequencing 
Compared to the traditional Sanger technology, NGS gives much greater 
speed and throughput at much lower costs per base. The NGS approach 
altogether omits the cloning step that creates bias and is very labor intensive 
and expensive when a larger number of reads is needed, for example, de novo 
genome sequencing, transcriptomics, and metagenomics. The most popular 
NGS platforms are Roche 454, Illumina (former Solexa), and Applied 
Biosystems (AB) SOLiD. In the 454 system, fragments of DNA are ligated with 
adapters and then bound to beads. Then DNA are amplified in the emulsion 
PCR on bead surface. Each bead with amplified fragment is then positioned in 
a picotiter plate, which further undergo pyrosequencing. The emitted light from 
synthesis during sequencing is detected as nucleotide signal (Wheeler et al. 
2008). The Illumina platform uses a solid-phase bridge PCR technology to 
amplify DNA fragments hybridized via adapters on a slide. Thereafter 
sequencing these amplified clusters by DNA polymerase using cleavable 
nucleotide analogs with different fluorescent labels. The emitted light and its 
position are recorded (Bentley et al. 2008). The ABI SOLiD also uses emulsion 
PCR on beads for amplification of the target libraries, but utilizes ligations for 
the actual sequencing. Specifically, sequential annealing and ligation of 
fluorescent labeled oligonucleotide probes are lighted to the DNA fragment 
immobilized on a glass support, The based are no longer sequentially 
interrogated, but at spaced intervals. The complete sequence is generated 
from overlapping of series of ligations (Valouev et al. 2008). The output of 
every sequencing technology is generally called read, which contains the 
information of the sequence identifier, sequence letters (bases), or numbers 
and quality values. The read length of 454 is longer, from 100bp (first model) to 
1,000bp (latest model), while the read length of Illumina (HiSeq) and SOLiD is 
about 50-150bp. Moreover, the read format from SOLiD is different from the 
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other two, usually called color space, while base space is used for 454 and 
Illumina. Depending on different sample library preparation methods, there are 
single-read, pair-end, or mate-pair sequencing, which allow different length of 
insert sizes. 
NGS technology provides opportunities for deeper studies of genetics and 
potential clinical application (Ozsolak et al. 2011). In cancer genome, common 
mutations have numerous forms, including and not limited to SNVs, small 
insertions and deletions, copy number changes, alternative splicing, DNA 
rearrangement, and chromosome structural variants (Hawkins et al. 2010). 
RNA-Seq can be used in NGS to sequence cDNA of transcriptome and reveal 
various aspects of dynamic transcriptome (Nagalakshmi et al. 2008).  
The epigenetics, including DNA methylation, histone modifications, and 
chromatin remodeling can also be studied by NGS through bisulfite 
sequencing and ChIP-Seq. Bisulfite sequencing discovers methylated 
nucleotides by bisulfite treatment of DNA (Krueger et al. 2012). ChIP-Seq 
combines chromatin immunoprecipitation with NGS to identify the binding sites 
of DNA-associated proteins. ChIP-Seq is widely used for finding transcription- 
factor binding sites, histone modifications, and also some of the DNA 
methylation methods (Gerstein et al. 2012).  
Besides genome and epigenetics, posttranscriptional RNA editing, including 
base insertion, deletion, and substitution is common in transcriptome (Li et al. 
2009). RNA editing will change the exon sequence and may lead to alteration 
in amino acids. The miRNA also post-transcriptionally regulates gene 
expression. It is likely that cellular processes are tightly regulated at the 
genetic, epigenetic, and transcriptome levels that interact in a complex 
network (Mattick 2004). NGS technology is advantageous for integrated 
studies of the genome, epigenetics, and transcriptome, which reveal biological 
mechanisms at multiple levels. The progress of NGS also raises challenges in 
bioinformatics to analyze such large-scale data (Pop et al. 2008).  
NGS technology is continuously evolving by updating sample preparation, 
library protocols, and developing design of sequencers. Improvements in 
sequencing technologies and bioinformatics analysis tools will lower the cost, 
enhance the sensitivity and accuracy of detecting variances. Furthermore, the 
third generation sequencing technology is now also commercially available, for 
example PacBio RS II from Pacific Biosciences (Eid et al. 2009). It is based on 
single molecule real time (SMRT) sequencing technology. It has the unique 
feature in producing much longer sequencing reads, and detecting DNA 
modifications (Feng et al. 2013). 
1.3.2.1 miRNA sequencing  
The miRNA sequencing technology (miRNA-seq) has given new opportunities 
to quantify the expression of known miRNAs,	   discover nucleotide variations 
(including RNA editing, 3’ and 5’ modifications) as well as to predict novel 
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miRNAs. Compared to miRNA microarray, miRNA-seq offers the advantage of 
finding novel miRNAs. Moreover, it avoids the probe design challenges caused 
by miRNA sequence characteristics. Furthermore, variants of known miRNA, 
which may be caused by RNA editing, can change their sequences or 
expression levels and thus alter their ability to regulate gene expression (Wu et 
al. 2008). The known miRNA annotations from miRBase are required to find 
differentially expressed miRNAs (Kozomara et al. 2011). It is known that 
isomiRs are common for miRNAs and the functional isomiRs may not be 
annotated in miRBase (Kuchenbauer et al. 2008; Morin et al. 2008). 
As the deep sequencing generates millions of reads, the real challenge is now 
about how to adequately analyze and interpret data. The basic steps behind 
the analysis of miRNA-seq can be summarized in three stages: (i) reads 
preprocessing (trim adaptors, quality check, etc.) and mapping to reference 
genomes; (ii) analysis of known miRNAs, such as differential expression test, 
isomiR discoveries; and (iii) prediction of novel miRNA on the basis of negative 
free energy and structure. The results of second and third stages are heavily 
dependent on the quality of the first stage. The mapping of miRNA-seq has its 
own bioinformatics challenge because the length of miRNA is short. The 
sequencing output is longer and needs trimming. Also the methods and 
parameters of mapping effects the results of following steps significantly 
(Williamson et al. 2013). Current analysis tools are designed to be easy to use, 
but with loss of flexibility to users to choose methods and decide the 
parameters. This means the result and performance of the analysis tools are 
heavily dependent on the data (species) and it is very difficult to assess the 
results from different tools (Li et al. 2012). There are still other issues that can 
be used for the improvement of current analysis tools such as supporting 
colorspace reads. Based on the above facts, we find the existing methods are 
not flexible enough and need a more adjustable workflow for processing 
miRNA-seq data.  
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2. Aims of the study 
 
The aim of this project was to study human miRNA functions in HPV oncogene 
E5 induction by microarray and identifying HPV miRNAs by NGS with suitable 
bioinformatics analysis. The specific objectives are:  
 
l Evaluating the E5 effects on human epithelial cells in the time series 
(0-96h) in mRNA and miRNA microarray.  
 
l Designing flexible analysis workflow for miRNA sequencing data.  
 
l Discovering novel HPV miRNAs from tissue samples by high 
throughput sequencing. 
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3. Methods  
 
Summary of methods used in this thesis: 
 
Microarray expression analysis (I) 
  Human miRNA and mRNA microarray preprocessing (I) 
  Differentially expressed miRNA/mRNA analysis (I) 
Functional annotation analysis of gene lists (I, III) 
Prediction of human miRNA targets (I) 
miRNA sequencing data analysis workflow design (II) 
miRNA sequencing by SOLiD platform (III) 
Mapping and preprocessing the SOLiD sequencing data (III) 
Prediction of candidate viral miRNAs (III) 
Prediction of novel viral miRNA targets (III) 
 
Dataset analyzed in this thesis: 
NCBI GEO database  
miRNA/mRNA microarray data (I)      GSE24908 
Public miRNA sequencing data (III)   
  Human SOLiD dataset      GSE22145 
Human Solexa dataset      GSE16579 
Arabidopsis thaliana Solexa dataset   GSE19694 
HPV miRNA sequencing data (III)      GSE42380 
 
3.1 Microarray analysis (I) 
Microarray slides were scanned by Axon GenePix 4200 AL scanner (Molecular 
Devices, Downington, PA). Images were analyzed by the software 
GenePixPro® 6.0 (Molecular Devices) and the output data were then imported 
into R software (R Core Team 2013) and preprocessed by the Bioconductor 
package Limma (Smyth 2004). For finding the differentially expressed genes, 
empirical Bayes test was utilized (nominal p-value < 0.001), and for miRNA, 
FDR model was applied (p-value < 0.01 after Benjamini-Hochberg correction) 
between E5-expressing and control cells in each time point in Table 1.  
 
Table 1. Summary of miRNA and mRNA experiment design in time series.  
 0h 2h 4h 24h 48h 72h 96h 
miRNA microarray x  x x x x  
mRNA microarray x x x x x x x 
 
3.2 Functional annotation analysis of gene lists (I, III) 
Functions of interesting genes were analyzed by the DAVID 6.7 annotation 
tools (Dennis et al. 2003; Huang da et al. 2009) to identify related and 
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interesting biological functions. Default DAVID parameters were utilized. In 
Paper I, the genes are an intersection of predicted targets and differentially 
expressed genes. In Paper III, the genes are predicted targets of miRNAs.  
3.3 Prediction of cellular microRNA targets (I) 
Putative targets of each human miRNA were predicted by using eight widely 
used algorithms in default settings for human miRNAs: 
DIANA – microT (Maragkakis et al. 2009) 
miRanda (Betel et al. 2008) 
miRDB (Wang et al. 2008) 
miRWALK (Dweep et al. 2011) 
PicTar (Krek et al. 2005) 
PITA (Kertesz et al. 2007) 
RNA22 (Miranda et al. 2006)  
TargetScan (Grimson et al. 2007). 
3.4 miRNA sequencing data analysis workflow design (II) 
The detailed processing schemes of the miRNA sequencing workflow, which 
we named miRSeqNovel, were described in Paper II (Figure 1 in Paper II). In 
general, workflow is designed in R and contains three major parts: data 
preprocessing, known miRNA analysis, and novel miRNA prediction. This 
workflow integrated some available methods/software into its pipeline and also 
tried to be extendable to other methods. For data preprocessing, the mapped 
result in SAM/BAM formatted output (Li et al. 2009) from Illumina/Solexa data 
can be read into R. For known miRNAs annotated in miRBase, the read counts 
for each miRNA will be extracted to build new tables, which can be directly 
used to find differentially expressed miRNAs as well as isomiRs expressions. 
For predicting novel miRNAs, there are two strategies to find the pre-miRNA 
sequences: to look for pairs of mapped reads within a certain range of each 
other and for a mapped read whose distance from its closest mapped read is 
longer than the defined gap, the genomic regions upstream and downstream 
of the reads are searched for possible sequences forming a hairpin secondary 
structure. We applied the RNAfold program in ViennaRNA (Hofacker 2003) to 
validate the hairpin structures of the predicted pre-miRNAs and only keep 
those with similar character to know miRNAs. All cited software packages are 
listed here: 
RNA2MAP (now part of Lifescope software (Life Technologies 2013)) 
MaToGff (now part of Lifescope software (Life Technologies 2013))   
Limma (R/Bioconductor package (Smyth 2004)) 
Biostrings (R/Bioconductor package (Pages et al. 2013)) 
GenomicRange (R/Bioconductor package (Aboyoun et al. 2013)) 
edgeR  (R/Bioconductor package (Robinson et al. 2010)) 
DESeq (R/Bioconductor package (Anders et al. 2010)) 
RNAfold (part of ViennaRNA (Lorenz et al. 2011)) 
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3.5 miRNA sequencing by SOLiD platform (II) 
A total of 12 samples: one of HPK IA cells, one of HPK II cells (Dürst et al. 
1987) and ten FFPE tissue samples, were used for preparing the small RNA 
libraries and subsequently ligated to adaptors of the SOLiDTM Total RNA-Seq 
kit (Ambion, Austin, TX). Next, small RNAs were reverse transcribed into 
cDNA libraries, size selected, and amplified with PCR primers containing the 
barcodes. Libraries were prepared for emulsion PCR (emPCR) according to 
SOLiD sequencing instructions followed by sequencing using the SOLiD 4 
instrument (Life Technologies, Carlsbad, CA). 
3.6 Mapping and preprocessing the SOLiD sequencing data (III) 
We used SOLiD small RNA pipeline (RNA2MAP) with default parameters to 
map the SOLiD colorspace reads that included quality filtering and adapter 
trimming steps. The viral reference genome was constructed by concatenating 
393 complete papillomavirus genomes retrieved from NCBI, including known 
subtypes and isolates of HPV and papillomaviruses in other species 
(Supplementary Table S1 in Paper III). Mapped results in Ma format were 
converted to GFF files using MaToGff (Applied Biosystems), which was further 
used as an input for miRSeqNovel. The SOLiD raw data is publicly available at 
GEO, series record GSE42380. 
3.7 Prediction of candidate viral miRNAs (III) 
We predicted novel virus-encoded miRNA candidates from the small RNA 
sequencing data using miRSeqNovel’s novel miRNA prediction function 
(Paper II). Due to lack of knowledge of HPV miRNA, we performed the 
prediction by using human and other miRNA characters. The prediction was 
done twice in two sets of parameters. In the first round, reads with counts less 
or equal to three in each library were considered as background and not used 
for prediction. To predict pre-miRNA candidates in miRSeqNovel, 40nt was 
used as the gap length for strategy one and 100nt was used as the upstream 
or downstream length for strategy two. Candidates shown at least in two 
libraries were further studied for their structures. We selected the candidate 
miRNAs for further validation based on the first round of predictions. In the 
additional round, reads from all 12 libraries were pooled together, and then 
reads with counts less or equal to two were discarded. Subsequent steps were 
performed similarly as in the first run, except that pre-miRNAs were extended 
to cover the reads overlapping with the predicted region.  
3.8 Prediction of novel viral miRNA targets (III) 
Human target genes of novel viral miRNAs were predicted using TargetScan 
custom miRNA prediction methods (Lewis et al. 2005). Putative targets within 
the viral genome were predicted using TargetScan Perl script. 
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4. Result 
	  
4.1 E5 effects on human miRNA expression 
The expression of human cellular miRNA was studied in HPV 16 E5 containing 
HaCaT cells as compared to controls by Agilent human miRNA microarray. 
The miRNA expression was considered significantly changed if the p-value 
was <0.01 after FDR correction (Benjamini-Hochberg) (Table 1 in Paper I). In 
total, 13 differentially expressed miRNA were shown in 0, 24, 48 and 72 hours 
after E5 induction in microarray analysis (Table S3 in Paper I). They are 
hsa-mir-146a (up), hsa-mir-203 (down), hsa-mir-324-5p (down), hsa-mir-200c 
(up), hsa-mir-214 (up (Peng et al. 2012)), hsa-mir-624 (up), hsa-mir-539 (up), 
hsa-mir-433 (up), hsa-mir-23b (down, previously reported in (Au Yeung et al. 
2011)), hsa-mir-30a-5p (down), hsa-mir-19a (down), hsa-mir-106a (down), and 
hsa-mir-107 (down). All of them were further validated by qPCR at the same 
induction time point and one more at four hour (Table 2 in Paper I and Figure 
2). From those, we selected hsa-mir-146a, hsa-mir-203, and hsa-mir-324-5p 
for further investigation based on their biological relevance. The hsa-mir-146a 
was constantly upregulated; while the hsa-mir-324-5p was constantly 
downregulated in E5 inducted cells at all the time points. And the hsa-mir-203 
remained unchanged during the initial 24 hours of the experiment but was 
repressed at later stages (48 and 72 hours). 
4.2 Integration of differentially expressed mRNAs and miRNAs  
Similar to time series microarray studies of miRNA, the expression of mRNAs 
was also analyzed in HPV 16 E5 induced HaCaT cells compared to controls by 
Agilent human mRNA microarray (Table S1 in Paper I). In addition to time 
points used in miRNA studies, three more time points (2, 4 and 96h) were 
applied to mRNA study. The mRNA expression was considered as significantly 
changed by the threshold of modest p-value <0.001 to minimize the type I 
errors (Table 1 in Paper I). qRT-PCR (32 genes) and western blotting (6 
proteins) validation were performed with at the same time point of mRNA 
microarray with one more at 36 hours (Table 3 in Paper I). 
Next, putative microRNA targets were predicted using eight distinct algorithms 
(see methods) for chosen miRNAs. Then the target lists were intersected with 
different expressed gene lists, resulting in 101, 79, and 176 putative targets of 
hsa-mir-146a, hsa-mir-324-5p, and hsa-mir-203, respectively (Figure 1 and 
Table S4 in Paper I). 
Functional annotation analysis results of these targets revealed that they were 
enriched in cell adhesion, and cell cycle (hsa-mir-146a); cell junction, cell 
migration, and cell motility (hsa-mir-203); cell death, and cell adhesion 
(hsa-mir-324-5p) (Table S5 in Paper I). 
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To find miRNA involved regulation networks in HPV 16 E5 induction, we 
compared the expression trend of the differentially expressed miRNA and their 
predicted targets in differentially expressed mRNAs. We assumed that 
functional miRNAs and their regulated targets expression would be negatively 
correlated in the time points. The Figure 3 plots all negatively correlated 
miRNA-mRNA pairs for all the 13 miRNAs. 
4.3 miRSeqNovel workflow and its performance on public data 
As the sequencing reads are usually longer (35nt, SOLiD4) than mature 
miRNA lengths (18-22nt), the reads need trimming first. Then reads can be 
mapped by any preferred and well-documented mapping software, e.g. 
RNA2MAP/ Lifescope , Bowtie/ Bowtie2, (Langmead et al. 2009; Langmead et 
al. 2012) or BWA (Li et al. 2009). This ensures that users can optimize the 
preprocessing (trim adapters, quality filtering) and mapping without any 
limitations and utilize sequencing data from multiple platforms, including 
SOLiD (“csfasta” format), and Illumina/Solexa (“fastq” format) platforms, 
against any reference genome. Before predicting novel miRNAs, reads 
mapped to known noncoding RNAs and exon regions are filtered according to 
Ensembl annotation (Flicek et al. 2011) (optional step). The remaining reads 
will be used as the input for novel miRNA prediction. Next, miRSeqNovel 
screens mapped reads to find candidate miRNA precursor sequences by 
checking their secondary structures. By assigning different sets of predictive 
parameters optimized for animal or plant genomes, we demonstrated that 
miRSeqNovel could successfully predict most known miRNAs and find 
conservative novel candidates. 
We tested miRSeqNovel on three SOLiD/Solexa miRNA sequencing datasets 
of human/Arabidopsis samples from NCBI GEO datasets. The results, script 
used, input files, and user manual are available online 
(http://sourceforge.net/projects/mirseq/files/). To discover differentially 
expressed miRNAs, many statistical methods could be applied to the 
expression, presented by read counts, of known miRNAs annotated in the 
miRBase database (Kozomara et al. 2011). miRSeqNovel by default uses 
edgeR (Robinson et al. 2010) and DESeq (Anders et al. 2010), both of which 
are widely used Bioconductor packages for analyzing sequencing data. 
Moreover, miRSeqNovel-built count tables could also be used in other 
methods that might use Bioconductor/R. In human SOLiD dataset (GSE22145, 
SOLiDv2, 35nt, 6.6M reads) (Marcet et al. 2011), we successfully found 
hundreds of differentially expressed known miRNAs (miRBase V16) by edgeR: 
882 out of 2854 annotated mature miRNAs, 172 out of 267 most abundant 
isomiRs, and 481 out of all 812 common isomiRs. We evaluated the novel 
miRNA finding function of miRSeqNovel on a set of Solexa miRNA sequencing 
data from human cancer cell lines HeLa, MCF7 and U2OS (GEO accession 
number GSE16579, Illumina Genome Analyzer, 35nt, 14.1M reads) (Mayr et al. 
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2009). miRSeqNovel successfully predicted 692 out of 882 (78.5%) known 
miRNAs expressed in this library. Additionally, miRSeqNovel predicted the 
presence of 418 novel candidate miRNAs. However, 190 previously reported 
candidate miRNAs were not predicted by miRSeqNovel. This could either be 
because the predicted hairpins are not the ones annotated in the miRBase, or 
because the matching percentage between the two paired sequences is lower 
than the given threshold. It is important to note that many of these 190 miRNAs 
were originally predicted by other methods but they have not yet been 
experimentally validated (Jima et al. 2010; Stark et al. 2010; Witten et al. 2010). 
For plant data, we used Arabidopsis thaliana (GSE19694, Illumina Genome 
Analyzer, 35nt, 3.1M reads) (Zhang et al. 2010) Solexa miRNA sequencing 
dataset. We successfully found 141 out of 180 (78.3%) known miRNAs 
presented in this data, along with an additional 371 candidates found by 
another set of parameters optimized for plant. 
4.4 SOLiD sequencing of HPV samples 
The total number of reads from SOLiD deep sequencing in HPK IA and HPK II 
cell lines and FFPE tissue samples varied from 7 million to 97 million, 
altogether 500 million reads (Table 1 in Paper III). The number of total reads 
mapped by RNA2MAP to the papillomavirus reference genome ranged from 
61 thousands to 1.4 million, roughly 1~2 % in each library.  
4.5 Prediction of novel viral miRNA candidates 
The mapping result from sequencing was used to predict novel viral miRNA 
candidates in miRSeqNovel (Paper II). We performed two rounds of 
predictions to determine whether the pre-miRNA should be extended to cover 
low count reads (see Methods). Putative HPV miRNAs for further studies were 
selected based on the clinical relevance of HPV types, particularly HPV 16. 
The results were finally combined, which revealed a total of nine novel putative 
HPV-encoded miRNAs (Table 2, Supplementary Table S7, Supplementary 
Fig.S2, Supplementary Fig.S3 in Paper III). The pre-miRNA sequences were 
named following the nomenclature instructions in miRBase (Kozomara et al. 
2011), such as HPV16-mir-H1 for pre-miRNA, and HPV16-mir-H1-1 for mature 
miRNA.  
The HPV type that is most important clinically, HPV 16, encoded five of the 
selected candidates. Two of the candidates were studied in more detail: 
HPV16-mir-H1, encoded by a region within the E1 gene on the positive DNA 
strand, and HPV16-mir-H2, encoded by the negative strand complementary to 
the LCR (Figure 4). Interestingly, HPV16-mir-H2 coding sequence was found 
in HPV 16 isolates, but there is a one-nucleotide deletion in the mature miRNA 
sequence in the prototype HPV 16 genome (NC_001526.2).  
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Figure 4. Locations of five predicted HPV 16 novel miRNAs 
 
Locations of HPV16-mir-H1-1 and HPV16-mir-H2-1 in the viral genome are 
shown as blue bars in Figure 4. The mature HPV16-mir-H1-1 miRNA is located 
in the loop region of HPV16-mir-H1 pre-miRNA as suggested by miRSeqNovel 
prediction (Supplementary Table S7 and Supplementary Fig.S4 in Paper III). 
Other isomiRs in the HPV16-mir-H1 are also found in the loop region. On 
account of the low read counts in sequencing data, it was challenging to 
distinguish mature miRNA and star miRNA from RNA degradation background. 
Because of the background, we further checked whether the predicted miRNA 
is correct by screening this with VMir (Sullivan et al. 2005), and found that the 
mature HPV16-mir-H1-1 miRNA, not the isomiRs, is located in the arm region 
of a shorter precursor sequence (Supplementary Fig.S4 in Paper III).  
HPV16-mir-H3 is localized in the LCR, HPV16-mir-H5 in the E1 coding region, 
and HPV16-mir-H6 in the antisense strand complementary to L1 (Figure 4). 
HPV6-mir-H1 is localized in the antisense strand of HPV 6 E1 region. 
HPV38-mir-H1 coding sequence is harbored in antisense of E7 region. The 
coding sequence for HPV45-mir-H1 is located within the L1 region. 
HPV68-mir-H1 is localized in HPV 68 L1 coding region. 
Five HPV miRNA candidates were further validated by TaqMan MicroRNA 
assays (Method in Paper III) for putative mature miRNAs. Four out of the five 
miRNAs were presented in cell lines and tissue samples (Table 3, Table S8 in 
Paper III). All predicted viral microRNAs were detected at high cycle counts in 
qPCR, suggesting fairly low expression levels in tissue samples. 
HPV16-mir-H1-1 and HPV16-mir-H2-1 coding regions were further confirmed 
by PCR amplification of the relevant HPV regions followed by Sanger 
sequencing for a representative set of samples in cell lines and several tissue 
samples (Table 3 in Paper III). 
HPV genotypes in the tissue samples were identified by a sensitive assay 
recently developed by our group (Ritari et al. 2012), as well as a Luminex 
based genotyping assay (Method in Paper III). As expected, HPV types 16 and 
18 were the most frequently occurring genotypes, and several samples 
harbored two HPV types (Table 3 in Paper III).  
We performed in situ hybridization (Method in Paper III) in tissue samples for 
HPV16-mir-H1-1 and HPV16-mir-H2-1 (Table 4 in Paper III). Cytoplasmic 
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signals for HPV16-mir-H1-1 were detected in several tissue samples, often 
colocalizing with p16INK4A (Figure 2 in Paper III), which is a surrogate marker 
for high-risk HPV. The encoding region for HPV16-mir-H1 is located within the 
E1 gene, a probe specific for E1 mRNA was used as the control in altogether 
ten tissue samples (Figure S5 in Paper III). The negative signals of the E1 
mRNA probe confirmed the specificity of our hybridization conditions. The 
HPV16-mir-H1-1 signal in our analysis also localized differently from a 
previously published work on E1 mRNA signal (Coupe et al. 2012). Low level 
expression of HPV16-mir-H2-1 was detected in one SCC tissue (Figure 2 in 
Paper III). Human miR-205 was used as a positive control for miRNA 
expressed in cervical epithelium (Xie et al. 2012), which also showed a 
different pattern between disease and healthy tissues.  
4.6 Prediction of viral miRNA targets  
We searched for targets of HPV16-mir-H1-1 and HPV16-mir-H2-1 by 
TargetScan (Grimson et al. 2007) . Both of these miRNAs have a unique target 
fingerprint of 137 and 176 genes, respectively, in the human genome 
(Supplementary Fig.S8, Supplementary Table S9). Interestingly they share 15 
predicted targets: CDC2L6, EIF2C1, IMPAD1, BNC2, SNX27, TNRC6B, 
BACH2, CYP26B1, DDX19B, FGF7, PBRM1, PHACTR2, RBM3, RGS7BP, 
and TEAD1. Prediction of target sequences in the HPV 16 genome identified 
four target sequences for HPV16-mir-H1-1, two of which are in the E5 gene 
and two in the L1 gene. HPV16-mir-H2-1 had two targets in the viral genome; 
one in the LCR region and the other located in the L1 gene. 
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5. Discussion 
Viruses are parasites and thus dependent on the host cellular machinery to 
complete their life cycle. Therefore, complex relationships have evolved 
between viruses and the host cells. The role of miRNAs has added yet another 
dimension to the complexity of viral host interactions. 
In Paper I, the effect of HPV16 E5 oncoprotein on the expression of cellular 
protein-coding genes and miRNA in HaCaT epithelial cell was investigated in 
genome-wide microarray experiments. Among cellular miRNA, we further 
validated and investigated the altered expression of hsa-mir-146a (constantly 
induced by E5), hsa-mir-324-5p (constantly repressed by E5), and hsa-mir-203 
(repressed at late time points). Functional annotation analysis of targets of 
these miRNAs revealed that they were enriched in cell adhesion, cell junction, 
cell migration, and cell motility. The same dexamethasone-inducible promoter 
was present in both HaCaT-E5 and HaCaT-E5 cell lines and both cell lines 
were induced identically, so the effect of dexamethasone should theoretically 
be subtracted when you compare the two cell lines. Nothing is expressed from 
the empty vector in control cells by dexamethasone induction but other 
possible effects of dexamethasone might appear in both cell lines. 
Strong upregulation of hsa-mir-146a has been continuously shown during the 
time frame of 0-96h in our study. This microRNA has been previously 
investigated in the regulation of immune responses in epithelial disorders 
(Sonkoly et al. 2008). It has been found to be upregulated in breast, pancreatic, 
and prostate cancers (Volinia et al. 2006; Lajer et al. 2012), and 
downregulated in androgen-dependent prostate cancers (Lin et al. 2008). It 
has also been found to be upregulated in cervical cancers (Lajer et al. 2012) 
and to promote cell proliferation when introduced into cervical epithelial cell 
lines (Wang et al. 2008). Hsa-mir-146 expression is induced by ligands of a 
subset of toll-like receptors (TLR) recognizing bacterial antigens, as well as by 
TNF-α and IL-1β in a NFκB-dependent manner (Taganov et al. 2006). Indeed, 
we were able to confirm that TNF-α stimulation in E5 cells where hsa-mir-146a 
expression had been inhibited resulted in considerable activation of the 
downstream kinase p38 and modest activation of ERK1/2 (Table 3 in Paper I). 
This shows that upregulation of hsa-mir-146a by E5 may play a significant role 
in attenuated immune response in HPV infections. 
A less studied species, hsa-mir-324-5p, was identified as constantly repressed 
in E5-expressing cells. Another study also confirmed its repression in HPV 
positive samples (Lajer et al. 2012). Hsa-mir-324-5p is a negative regulator of 
the oncogenic Hedgehog pathway in neuronal tumors (Ferretti et al. 2008). 
Among the putative hsa-mir-324-5p targets, we showed strong upregulation of 
N-Cadherin gene and protein expression (Table 3, Figure 2 &3 in Paper I), in 
agreement with downregulation of hsa-mir-324-5p. Expression of another 
putative target of hsa-mir-324-5p, E-Cadherin, was increased at the protein 
level (Figure 2 & 3 in Paper I). Our data indicates that the HPV E5 oncogene 
34	  
	  
may repress hsa-mir-324-5p expression in cervical epithelial cells and thus 
contribute to the carcinogenic process. Altogether, our results suggest an 
involvement of hsa-mir-324-5p in the oncogenic functions of E5.  
Hsa-mir-203 was repressed in the later time points. Hsa-mir-203 was the first 
identified epithelium and skin specific miRNA (Sonkoly et al. 2007). It has 
tumor suppressor function and its downregulation has been observed in 
tumors (Furuta et al. 2010). A recent study proved that HPV E7 downregulates 
hsa-mir-203 (Melar-New et al. 2010). We observed a slight induction of 
hsa-mir-203 target p63 in E5 induced cells. We further confirmed this by 
showing that p63 was abolished upon overexpression of hsa-mir-203 (Figure 6 
in Paper I). p63 is an important family of transcription factors that maintain the 
proliferation of basal epithelial cells, and the expression of p63 is a reduced 
correlate of E5 expression. This finding suggests a connection between HPV 
oncogene expression and diminished differentiation. 
Genome-wide expression data from microarrays or NGS, have been exploited 
to unravel the complex regulatory networks by miRNAs at a system level 
(Licatalosi et al. 2010). In Paper I, the integrative computational method used 
was based on the miRNA-mRNA correlation matrix in a time series expression 
profiles of miRNAs and mRNAs. The predicted miRNA targets have played a 
critical role in identifying the biological effects of miRNAs (Calin et al. 2006). 
Eight computational tools have been developed for the effective prediction of 
miRNA target sites in mRNAs (Paper I). We utilized several of these software 
in concert to identify miRNA functions through their targets, as described in 
Paper I. However, to reveal the regulatory networks by miRNAs, more 
experimental data is needed in addition to more elaborate statistical 
approaches. Single gene expression regulation is subject to various levels of 
control and may involve a mixture of multiple TFs and miRNAs, which make 
the finding difficult. The topological structures of regulatory networks include  
a hierarchical structure and motifs enrichment, such as feed-forward loops 
(Cheng et al. 2011). 
New results from high-throughput profiling of small RNAs using NGS 
technologies have given more supports to the diversity of miRNA variants, 
isomiRs (Lee et al. 2010). IsomiRs can be generated by several mechanisms 
such as differential processing by Dicer, or RNA editing. Though many miRNA 
variants are usually expressed in a low level compared to the mature miRNA, 
some isomiRs are relatively highly represented, differentially expressed, and 
thus might have biological functions (Morin et al. 2008). The isomiRs with 5′ 
end variants are more critical because the miRNA seed region will also be 
changed in these isomiRs. 
The first step in understanding the miRNA–mRNA regulations would be to find 
real miRNA targets, which is still a challenge from the perspective of the 
bioinformatics algorithms development. Currently, the widely used methods for 
miRNA target prediction rely on the seed sequence complementarity and 
35	  
	  
conservation across species. However, they generally have high false-positive 
rates and the results are not consistent among different methods. Some new 
statistical models and algorithms, such as Bayesian algorithm (Huang et al. 
2007), classification based algorithm (Hecker et al. 2013), and LASSO 
regression algorithm (Muniategui et al. 2012), try to combine the expression 
data generated from microarray or NGS to predict reliable connections 
between miRNA-mRNA pairs. Still, these methods cannot distinguish direct 
and indirect regulation by miRNAs. 
The development of NGS technologies have made it possible to identify 
miRNA target binding sites directly on a global scale by crosslinking and 
immunoprecipitation high-throughput sequencing (CLIP-Seq or HITS-CLIP) 
(Licatalosi et al. 2008). It utilizes UV-crosslinking between RNA and the protein, 
followed by sequencing the fragmentation of the crosslinked and 
coimmunoprecipitated RNA with the protein antibodies. Improved protocols 
also increased resolution by using photoactivatable ribonucleoside-enhanced 
crosslinking and immunoprecipitation, (PAR-CLIP) (Hafner et al. 2010) and 
individual nucleotide resolution UV crosslinking and immunoprecipitation 
(iCLIP) (Konig et al. 2010). PAR-CLIP employs photoreactive ribonucleoside 
analogs incorporated into nascent RNA transcripts to induce efficient 
crosslinking with RBPs and miRNPs. The iCLIP relies on the same 
crosslinking and immunoprecipitation methods as CLIP-Seq. When the RNA is 
reverse transcribed, iCLIP add 5’ adaptor to truncate at the crosslink site. This 
step allows identification of RNA-protein interaction sites at high resolution and 
low error rate. New bioinformatics approaches have been developed to 
analyze these kinds of data (Chou et al. 2013; Majoros et al. 2013). Using 
these technologies, new findings are constantly added to the miRNA target 
knowledgebase. Interestingly, miRNAs bind more often to coding exons than 
previously thought, and many binding sites seem to deviate from the known 
target prediction rules (Majoros et al. 2013). Combining CLIP-seq results with 
miRNA/gene expression results from microarray or miRNA/RNA-seq will give 
more robust result of miRNA targets and the about the functionality of the 
identified binding sites.  
MiRNA characteristics make them attractive for viruses to regulate gene 
expression. Since they are small in size, they can easily be fitted in the small 
size genomes. Moreover, miRNAs are non-immunogenic and they take 
advantage of the host regulatory mechanism. Furthermore, they can target 
both virus-encoded mRNAs and host gene transcripts. Many dsDNA viruses, 
such as polyomaviruses, encode miRNAs (Sullivan et al. 2005; Seo et al. 2008; 
Chen et al. 2011). Papillomaviruses have been suspected to encode their own 
miRNA because they have dsDNA genomes, they replicate mainly in the 
nucleus, and they have the ability to establish persistent infection and latency 
(Cullen 2006). However until now no papillomavirus miRNAs have been 
validated. Utilizing miRNA sequencing technology will give the advantages of 
identifying novel papillomavirus encoded miRNA over other traditional 
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methods.  
Since the early days of miRNA sequencing, many bioinformatics tools have 
been developed to identify miRNAs from millions or even billions of 
sequencing reads. Several of them have been compared and reviewed in (Li et 
al. 2012) and (Williamson et al. 2013), including miRDeep (Friedlander et al. 
2008), miRDeep2 (Friedlander et al. 2012), miRanalyzer (Hackenberg et al. 
2009), miRExpress (Wang et al. 2009), miRTRAP (Hendrix et al. 2010), DSAP 
(Huang et al. 2010), mirTools (Zhu et al. 2010), MIReNA (Mathelier et al. 2010), 
miRNAkey (Ronen et al. 2010), and mireap (Li et al. 2012). Our new analysis 
workflow for miRNA sequencing data processing in R environment was named 
as miRSeqNovel. Unlike many available tools, miRSeqNovel aims at being a 
universal workflow instead of being data source specific. It supports results 
from different mapping methods with different sets of parameters. It has no 
limitation to what reference genome(s) are used. This is the first miRNA-seq 
analysis workflow implemented in R/Bioconductor, and it is compatible with all 
operating systems. When researchers select the optimal methods for 
miRNA-seq analysis, it is always recommended to understand and verify the 
software limitations and their specific requirements. 
From the miRNA-seq data, the sequencing reads number can easily quantify 
expression levels of known miRNAs with annotation in miRBase. The benefit 
of sequencing is the direct detection of isomiR expression. miRSeqNovel 
considers both annotated mature miRNA and isomiRs in differentially 
expressed miRNA findings. There are already widely used high-throughput 
platforms for miRNA analysis, Agilent/Affymetrix microarrays and NGS. It is 
important and very interesting to compare results between different microarray 
and NGS platforms. Every platform has its strengths and weaknesses, which 
might also lead to biases in the result. By using mature spiked-in miRNAs as a 
positive marker, people found Agilent was the most accurate platform 
(Leshkowitz et al. 2013). However, this result may be improved by applying 
future statistical methods and may be dependent on the spiked-in miRNAs 
sequences.  
Because miRNA biogenesis involves different mechanisms in different species, 
it is difficult to define a standard set of parameters for predicting novel miRNAs. 
miRSeqNovel uses fully customizable parameters on prediction of novel 
miRNA candidates. Moreover, it predicts conservative novel miRNA 
candidates without annotation of known miRNAs, which is useful for species 
with no miRNA annotations. Various computational analyses rely on machine 
learning approaches to identify novel miRNAs by utilizing all the information 
publically available in miRBase (Batuwita et al. 2009; Kadri et al. 2009; van der 
Burgt et al. 2009). However, annotation information in miRBase is updated 
biannually and still needs further experimental validation (Hansen et al. 2011). 
These methods rarely update their training data and few of them consider 
species-specific records.  
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In miRNA sequencing data, reads are usually mapped to hundreds of 
thousands of genomic locations. However, with a limited number of known 
miRNAs, it is still a challenge to capture novel miRNAs in silico (Chung et al. 
2011). When comparing the novel miRNA prediction result from available 
miRNA-seq software, the challenge is that methods are sensitive to the 
species selected, which can affect the performance. The overlap between 
individual prediction methods is much less than if combined, implying a high 
number of false positives (Li et al. 2012). The reason for this is that current 
miRNA sequencing methodology focuses solely on the mature sequence and 
the precursor is generally a theoretical prediction based on the information 
provided by the mapped read. Consequently, results can also be affected by 
the methods and parameters used for mapping (Williamson et al. 2013). In 
order to resolve the apparent discrepancy in predictions of novel miRNA, one 
needs better methods, both computational and experimental. Unlike previously 
published methods, miRSeqNovel performs conservative prediction and 
usually produces a higher number of potential miRNA candidates than other 
predicting methods, which use mathematical models to filter candidates. The 
prediction results of known miRNAs indicate that miRSeqNovel can give 
reliable results (around 80%) without further filtering based on comparing 
published sets of data.  
Screening for candidate HPV miRNAs, miRSeqNovel used current 
understanding of human miRNA and small ds-virus miRNA features. 
Accumulating miRNA sequencing data continuously corrects miRNA 
annotations in the miRBase (Kozomara et al. 2011). We considered the 
relative sequence abundance as one of the main criteria in prediction of 
mature miRNAs (Kuchenbauer et al. 2008). Predicting the precise features of 
novel miRNAs and star miRNA/isomiRs is challenging, as many candidates 
had low read counts. Solving this in the second prediction round, we combined 
all the libraries together using all sequencing reads. Comparison of the results 
of the first and second prediction rounds revealed advantages and 
disadvantages in both rounds. The second round will give a better prediction of 
pre-miRNA when star miRNA, is not fully covered by the pre-miRNA in the first 
round. However, in the second round, some low expression reads noise may 
add additional nucleotides to pre-miRNA leading to suboptimal RNA 
secondary structure such as HPV16-mir-H2. HPV16-mir-H1 was shown using 
both prediction runs. 
Viral miRNAs may also have non-canonical features that differentiate them 
from human miRNAs (Reese et al. 2010). Due to the low expression level of 
HPV16-mir-H1, it was not possible to establish its exact length. The precursor 
sequence of HPV16-mir-H1 is still a prediction and hence has uncertainties. 
This is similar to the known Merkel cell polyomavirus encoded MCV-mir-M1-5p, 
which was first predicted from VMir followed by validation (Seo et al. 2009). It 
was further identified by Illumina sequencing and validated by qRT-PCR. It 
exhibits a 5’end 2-nt shift from the VMir predicted MCV-mir-M1 mature 
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sequence (Lee et al. 2011). Further studies are needed to prove whether the 
isomiRs presented here could also exist and be functional under some 
conditions. 
Viral miRNAs are ideal tools for viruses for modulating both viral and cellular 
gene expression. Viral miRNAs of SV40 (Sullivan et al. 2005), Merkel cell 
polyomavirus (MCV) (Seo et al. 2009; Lee et al. 2011), JC virus, BK virus (Seo 
et al. 2008), and BPCV (Chen et al. 2011) share similar functions in negatively 
regulating viral early gene expression by targeting early transcripts (T antigen) 
with subsequent escape from host immune attack and facilitation of viral 
replication. Despite the lack of sequence similarity, HPV has similar genome 
size and similar gene functions to those of polyomaviruses, which suggests 
that HPV might encode miRNA with related functions.  
Entire tissue samples were used for these studies, while only a subset of these 
cells were infected. This caused low counts of sequencing reads for viral 
miRNA prediction, which can be improved by deeper sequencing. Robust 
signals of viral miRNAs were seen in cervical tissue in in situ hybridization, 
often colocalizing with and restricted to p16INK4a signal. In situ hybridization 
also showed altered distribution of human miR-205, which has been shown to 
promote proliferation of human cervical cancer cells (Xie et al. 2012). However, 
the signals in the in situ assays for the U6, miR-205, and HPV miRNAs cannot 
be directly compared as a measure of the expression level because the signal 
intensity also depends on the antibodies. 
Cellular targets of HPV-encoded miRNAs give an overview of their putative 
functions in regulating cellular gene expression. Gene ontology analysis of 
predicted cellular targets of HPV16-mir-H1-1 suggests important roles in host 
cell interactions of HPV16.This includes the cell cycle process, especially the 
M phase, which is important for viral infection (Pyeon et al. 2009). A set of 
predicted target genes are involved in regulation of immune functions of the 
host, such as T cell activation, and immune system development. Also, genes 
involved in epithelium development and cancer point to an auxiliary role of this 
miRNA in the onset of epithelial abnormalities and oncogenesis. It also shares 
the same target gene predicted for Merkel cell polyomavirus miRNA, PIK3CD, 
which is involved in activation of cell growth, survival, proliferation, and motility, 
in regulation of cell morphology, and in mediating host immune responses 
(Darmochwal-Kolarz et al. 2009). Further, HPV16-mir-H1-1 has two putative 
target sites within the E5 gene, suggesting that HPV-encoded miRNAs may be 
involved in activation of the Akt/PI3K pathway by the HPV 16 E5 oncogene 
(Kivi et al. 2008). 
HPV16-mir-H2-1 predicted cellular targets are also presented in similar 
pathways, like cell cycle process and M phase, and in immune regulation such 
as T cell activation and immune system development. Importantly, predicted 
target gene functions in cell migration and cell adhesion showed very similar 
functions in earlier studies (Kivi et al. 2008), suggesting a possible involvement 
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or interplay with the E5 oncogene. 
Expression levels of HPV-encoded miRNAs described here were low, which is 
reasonable given that even low levels may suffice to facilitate viral replication, 
and that their targets may also be important for viral replication. The predicted 
viral microRNA also target sites within the E5 gene, L1 gene, or LCR in the 
viral genome (Figure 1 in Paper III). Autoregulation of viral replication as 
shown for polyomavirus miRNA establishes latency (Skalsky et al. 2010). E5 
transcripts of genital papillomaviruses are always multicistronic (Wang et al. 
2011). How the HPV miRNAs target these particular regions would affect the 
expression of several viral genes and increase the possibility of pathogenesis 
of the papillomaviruses. 
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6. Conclusions 
 
Both microarray and NGS methods are suitable to study the genome-wide 
gene expression profiling. We believe that HPV 16 E5 oncogene contributes to 
carcinogenesis by several mechanisms that involve regulation of cellular 
miRNA and their target genes. Alterations in miRNA expression of HPV 16 E5 
oncogene seem to increase cell proliferation and tumorigenesis, and repress 
epithelial differentiation. As compared to microarray, NGS has technical 
advantages but there is still a need for better bioinformatics solutions. The 
miRNA-Seq has become a very popular tool to reveal the miRNA expression 
profiles and find novel miRNAs. miRSeqNovel is a fully customizable method 
implemented in R. It is flexible and easy to use given that the user is familiar 
with miRNA biology and R/Bioconductor basics. It accepts both colorspace 
(SOLiD) and basespace (Illumina/Solexa) data. It finds differentially expressed 
miRNAs and gives conservative prediction of novel miRNA candidates with 
customized parameters. We discovered novel HPV-encoded miRNAs by 
SOLiD 4 and further validated them by qRT-PCR and in situ hybridization. 
Biological functions of the predicted cellular target genes suggest a possible 
and significant role in the establishment of infection and in carcinogenesis. 
Viral miRNA are also tempting as possible targets for new antiviral drugs. 
These findings emphasize the need for further studies on HPV miRNA 
functions. 
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